0.8225 0 (0%) | 04-28 15:58 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.33 | 1-year : | 0.53 |
Resists | First : | 0.28 | Second : | 0.45 |
Pivot price | 0.09 | |||
Supports | First : | 0 | Second : | 0 |
MAs | MA(5) : | 0.1 | MA(20) : | 0.1 |
MA(100) : | 0.73 | MA(250) : | 3.04 | |
MACD | MACD : | -0.1 | Signal : | -0.2 |
%K %D | K(14,3) : | 15.7 | D(3) : | 23.6 |
RSI | RSI(14): 38.5 | |||
52-week | High : | 10.39 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMV ] has closed above bottom band by 42.7%. Bollinger Bands are 90.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.1 - 0.1 | 0.1 - 0.1 |
Low: | 0.08 - 0.08 | 0.08 - 0.08 |
Close: | 0.09 - 0.09 | 0.09 - 0.09 |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Tue, 26 Mar 2024
IMV INC (IMV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies Canada
Tue, 26 Mar 2024
IMV (TSE:IMV) Shares Down 1.8% - Defense World
Wed, 21 Feb 2024
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS ... - PR Newswire
Thu, 15 Feb 2024
BioVaxys Acquires Full Portfolio of Former IMV - Pharmaceutical Technology Magazine
Tue, 13 Feb 2024
BioVaxys snatches up 'bankrupt' IMV's preclinical and clinical assets - Pharmaceutical Technology
Mon, 12 Feb 2024
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the ... - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 12 (M) |
Held by Insiders | 1.017e+007 (%) |
Held by Institutions | 0.4 (%) |
Shares Short | 31 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.958e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -12 % |
Return on Assets (ttm) | 239.2 % |
Return on Equity (ttm) | -61.8 % |
Qtrly Rev. Growth | 329000 % |
Gross Profit (p.s.) | 49.34 |
Sales Per Share | -334.6 |
EBITDA (p.s.) | -1.53158e+007 |
Qtrly Earnings Growth | -4.6 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -33 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | -0.2 |
Dividend | 0 |
Forward Dividend | 311110 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |